GeoVax Labs Inc (GOVX)

[CarlCarlMcB]

Going up river $$$$$$ FISH ON $$$$$

[Trompete]

is this trash still listed? unbelievable

[CarlCarlMcB]

Lol

[XenaLives]

Three months with no fundamental change, the elastic on the jock strap is worn out.

[CarlCarlMcB]

Hold on to your jock straps $$$$$$$$

[StockLogistics]

.6902 intraday gap fill this week and looking at Late Feb for next opportunity imo

[carusso]

I have no information on these important questions.

[Sprincenatu]

How soon could they do it? Do they have the money for it?

[carusso]

Develop the clinical/health applications for their patents, monetize these patents.

[Sprincenatu]

What are they expected todo next?

[carusso]

You failed to read the News...

[Trompete]

it is hopeless, P&D on no news, will crash as always. Obsolete trash

[PennyPusher786]

Analysts calling for a minimum of $3 and a maximum of $8!!! LET'S GET IT!

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on GeoVax Labs and set a price target of $8.00.

Currently, the analyst consensus on GeoVax Labs is a Moderate Buy with an average price target of $5.50

In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.

[DK11]

Really nice here.

[KellySueNews]

https://www.marketscreener.com/amp/quote/stock/GEOVAX-LABS-INC-112977270/news/GeoVax-Receives-Notice-of-Allowance-for-Zika-Vaccine-Patent-42811350/

[TheRealMrPirate]

Ya I've heard that, and they're over 400 different strains of the flu too...I mean Covid, you know...variants...lol

[La Dolce Vita]

Might want to check your information. The Sudan Ebola virus is not the same as the Zaire Ebola virus. There are biological differences and as such the vaccines aren't interchangeable.

GOVX

[TheRealMrPirate]

In the works? The Ebola vaccine was already developed back in 2019'

[Trompete]

is this trash still listed????

[gr8investment]

Ebola is spreading, they have the vax in the works...nuff said

[subslover]

GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
October 26 2022 - 09:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.
Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others.

Wednesday, November 9, 2022, 4:30 PM EST

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13733113

Webcast: GeoVax Earnings Webcast

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through February 9, 2023. A telephonic replay of the call can be accessed by calling 877-660-6853 (domestic) or 201-612-7415 (international), using access code 13733113. The telephonic replay will be available until November 23, 2022.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Media Relations Contact:
Gina Cestari
6 Degrees
917-797-7904
[e-mail]

[TIZZUNI]

This Company is not garbage. This Company consists of dedicated, hard-working human beings, with the goal of producing effective medicines for the healing and survival of sick humanity.

[Trompete]

is this garbage still listed on nasdaq? Cannot believe it

[carusso]

Agree.

[La Dolce Vita]

You are welcome.

I watched the conference and it appears they have a chance of becoming a profitable biotech company.

The pipeline is quite robust, imo. Their approach of activating the T Cells stands to make their platform for vaccines be very valuable and very successful, if they can commercialize and develop their pipeline. All my opinion of course.

[carusso]

Thanks for sharing that link.

[La Dolce Vita]

The Investment conference begins in 10mins.

Tune in to the webcast with this link:


https://journey.ct.events/view/883f0eb3-d86b-41c6-906b-33bbce4c006e

$GOVX

[carusso]

Sounds good...

[La Dolce Vita]

A break and hold over $1.80 sets this up nicely for $2.30-2.50. Let's get it.

http://stocktwits.com/LaDolceVita7/message/484220525

[missile_systems]

THANK YOU SUBSY ;) !!!!!!!!!!!!!!!!
Message received and duly noted !
Have a Blessed weekend
Peace
ms

[subslover]

Fantastic call!

[subslover]

Fantastic call!

[Filterthenoise]

$GOVX... Big $$$ coming

GLTA

[easymoney]

You nailed it lol.

[Invest-in-America]

GOVX: Will likely DOUBLE from here by the Close today.
---------------------------------------------------------------------------------------------------------------------------
DISCLAIMER: BEFORE investing in ANY stock, please consult with MY (proven) 'Personal Financial Planner', below --- Mr. D. Harry!!! And, no matter WHAT that Stock may be, Harry's ADVICE is invariably the SAME!!!

[La Dolce Vita]

$GOVX ~ Huge move being made today.

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin®)

ATLANTA, GA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 2:30 p.m. Eastern Standard Time.

[carusso]

“From your lips...”

[La Dolce Vita]

*White House Seeks $44.5 Billion to Fight Covid and Monkeypox, Aid Ukraine --WSJ

That's good news for this ticker. Could see another huge run.

$GOVX

[Golden Cross]

fib retrace underway looks like

[StockLogistics]

Could go to .10 without Monkeypox demand

[carusso]

I hope not (.62), and i hope so (end of monkeypox).

[stock_diver]

Order in at .99! :}

[carusso]

Am guessing $1 on options...

But who knows???

[m1ocha]

Wow....is there a bottom?

[StockLogistics]

.62 cents, it is seeking the lower bollinger band on six month chart, probably on future news that monkey pox has peaked

[CarlCarlMcB]

Out break !!!!

[akamaii]

Move on please

[m1ocha]

Lucky to have sold this loser a couple of weeks ago. I may get back in under a buck.

[Myplace]

Don't follow this very much anymore after a 60K loss through thier repeated R/S ... But last I saw a few months ago we had 12.M shares , Now 25M ish. when did this happen... still have 200 shares I think. cost in excess of 60K over the years...

Tia, for any explanation...

[m1ocha]

Talking into an echo chamber but what time does this break 2 bucks today?